NASDAQ : ARNA

Arena Pharmaceuticals, Inc.

$99.99 USD

$0 (0.0%)

Volume
0
Average Volume
1.47M
Market Capitalization
$0
P/E Ratio
-8.83
Dividend Yield
0.00%
Price Target
$92.00
Year High
$100.00
Year Low
$45.50
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$8.59
Company Overview

NASDAQ

Amit Munshi

Biotechnology

Healthcare

ARNA

448

US

USD

https://www.arenapharm.com

18584537200

040047607

0001080709

Liquidity Metrics

0.06

8.59

8.59

3.39

0.00

Sales & Valuation

$54000

0.00

8.13

0.00

-9.55

Profitability

-$11.33

-$620.59M

-1149244.44%

-1141542.59%

-70.77%

-79.09%

P/E Metrics

-8.83

0.29

0.29

Analyst Price Target & Rating

$92.00

$100.00

$90.00

N/A

0/5

23 Analysts

8.68%

Poll Results

About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Stock

Arena Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing innovative therapeutic agents, specifically designed with distinct pharmacological and pharmacokinetic profiles, for a global patient population. Its extensive pipeline features several key investigational medicines. Etrasimod (APD334) is undergoing diverse clinical evaluations, including a Phase III study for ulcerative colitis, a Phase IIb/III trial for Crohn's disease, a Phase II trial for alopecia areata, a separate Phase III trial for atopic dermatitis, and a Phase IIb study for eosinophilic esophagitis. Olorinab (APD371) is currently in a Phase IIb clinical trial, targeting abdominal discomfort linked to irritable bowel syndrome. APD418 is progressing through Phase II trials for acute heart failure, while ... Temanogrel is also in Phase II development, addressing coronary microvascular obstruction. Furthermore, Ralinepag (APD811) is undergoing Phase III clinical assessment for pulmonary arterial hypertension. Arena maintains collaborative alliances with a range of entities, such as United Therapeutics Corporation, Everest Medicines Limited, Eisai Co., Ltd. and Eisai Inc., Boehringer Ingelheim International GmbH, Beacon Discovery, Inc., and Aristea Therapeutics, Inc. Established in 1997, Arena Pharmaceuticals, Inc. operates from its headquarters in Park City, Utah. As of March 11, 2022, the company functions as a subsidiary of Pfizer Inc.

Frequently Asked Questions

What is the current Arena Pharmaceuticals, Inc. (ARNA) stock price?

Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) stock price is $99.99 in the last trading session. During the trading session, ARNA stock reached the peak price of $100 while $99.97 was the lowest point it dropped to. The percentage change in ARNA stock occurred in the recent session was 0.0% while the dollar amount for the price change in ARNA stock was $0.

ARNA's industry and sector of operation?

The NASDAQ listed ARNA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ARNA?

|
|
|
|
|

How many employees does ARNA have?

Number of ARNA employees currently stands at 448. ARNA operates from 6154 Nancy Ridge Dr, San Diego, CA 84060, US.

Link for ARNA official website?

Official Website of ARNA is: https://www.arenapharm.com

How do I contact ARNA?

ARNA could be contacted at phone #18584537200 and can also be accessed through its website. ARNA operates from 6154 Nancy Ridge Dr, San Diego, CA 84060, US.

How many shares of ARNA are traded daily?

The average number of ARNA shares traded daily for last 3 months was 1.47M.

What is the market cap of ARNA currently?

The market value of ARNA currently stands at $0 with its latest stock price at $99.99